{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-029960","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-07-29T11:31:02+00:00","discovered_at":"2026-07-29T11:35:00.410068+00:00","generated_at":"2026-07-29T11:35:18.399650+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis Q2 2026 revenue $268M, operating loss $102M; eplontersen misses ATTR-CM endpoint","bullets":["Total revenue $268M (down 41% YoY); excluding one-time sapablursen payment, revenue up 56% YoY.","Operating loss from operations $102M vs income $140M in Q2 2025; non-GAAP operating loss $57M.","TRYNGOLZA net sales $5M in Q2, $32M in H1; DAWNZERA net sales $26M in Q2, $42M in H1.","Eplontersen CARDIO-TTRansform missed primary composite endpoint in overall population; nominal significance in monotherapy.","Zilganersen NDA under FDA Priority Review with PDUFA Sept 22, 2026; on track for launch this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-029960","json":"https://secwatch.observer/filing/0001140361-26-029960.json","markdown":"https://secwatch.observer/filing/0001140361-26-029960.md","text":"https://secwatch.observer/filing/0001140361-26-029960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/0001140361-26-029960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:35:18.399650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}